43rd Annual J.P. Morgan Healthcare Conference

01/15/2025 | 3:45pm PST / 6:45pm EST

Listen to the webcast

Events & Presentations

Financial Reports and Filings

Date Filing Title Downloads
02/10/2025 SCHEDULE 13G/A SCHEDULE 13G/A - Description RTF XLS PDF HTML XBRL
01/30/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
01/15/2025 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
01/02/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL

Latest News

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test Thumbnail

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Feb 06, 2025 | Products

Read more
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay Thumbnail

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Feb 05, 2025 | Corporate | Pipeline

Read more
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration Thumbnail

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Feb 05, 2025 | Products

Read more

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease."

— Paul J. Diaz
President and CEO, Myriad Genetics

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease."

— Paul J. Diaz
President and CEO, Myriad Genetics